1349
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1349)
Market Closed
8 Dec, 08:00
HKEX 
2. 93
HKD +0.01
+0.34%
- Market Cap
- P/E Ratio
0.09% Div Yield
895,000 Volume
0 Eps
2.92 HKD
Previous Close Day Range
2.93 2.97
Year Range
2.13 5.29
Want to track 1349 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
1349 closed today higher at 2.93 HKD, an increase of 0.34% from yesterday's close, completing a monthly decrease of -11.21% or 0.37 HKD. Over the past 12 months, 1349 stock gained 19.59%.
1349 pays dividends to its shareholders, with the most recent payment made on Aug 25, 2025. The next estimated payment will be in In 8 months on Aug 25, 2026 for a total of 0.0321 HKD.
The last earnings report, released on Aug 11, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XBER (EUR).
1349 Chart
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1349) FAQ
What is the stock price today?
The current price is 2.93 HKD.
On which exchange is it traded?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is listed on XBER.
What is its stock symbol?
The ticker symbol is 1349.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.09%.
What is its market cap?
As of today, no market cap data is available.
Has Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ever had a stock split?
No, there has never been a stock split.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | HKEX Exchange | - ISIN |
| Germany Country | - Employees | 10 Jul 2025 Last Dividend | - Last Split | - IPO Date |
There is no Profile data available for FDY.BE.
Contact Information
2025 © Marketlog. All Rights Reserved.
